# Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

Study · id `cardio:ct-nct02539966` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02539966](<https://clinicaltrials.gov/study/NCT02539966>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02539966

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

## Technical summary

Registry record NCT02539966. Non-randomized; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2019-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 272 participants (enrolled count; ClinicalTrials.gov record NCT02539966, source copy `cardio:ctgov-nct02539966-2025-04-04`, retrieved 2026-10-26)
- Started: 2015-03 (actual) (ClinicalTrials.gov record NCT02539966, source copy `cardio:ctgov-nct02539966-2025-04-04`, retrieved 2026-10-26)
- Primary completion: 2019-08 (actual) (ClinicalTrials.gov record NCT02539966, source copy `cardio:ctgov-nct02539966-2025-04-04`, retrieved 2026-10-26)
- Completion: 2024-09 (actual) (ClinicalTrials.gov record NCT02539966, source copy `cardio:ctgov-nct02539966-2025-04-04`, retrieved 2026-10-26)
- Countries: Australia; Belgium; Brazil; Denmark; France; Germany; Netherlands; Poland (ClinicalTrials.gov record NCT02539966, source copy `cardio:ctgov-nct02539966-2025-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02539966-2025-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
- Acronym: FANTOM II
- Condition: Coronary Artery Disease
- Intervention (Device): Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
- Lead sponsor: REVA Medical, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: REVA Medical, Inc. (`cardio:org-reva-medical-inc`)

## Provenance

Content hash: f772de07cb8c7c4a525323bbf02c1403b3b02b04fc4584b785e5051930b2826f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
